| Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy H Liu, Z Zhao, L Zhang, Y Li, A Jain, A Barve, W Jin, Y Liu, J Fetse, ... Journal for immunotherapy of cancer 7, 1-14, 2019 | 108 | 2019 |
| Ethnopharmacological importance of Xylopia aethiopica (DUNAL) A. RICH (Annonaceae)-A review J Fetse, W Kofie, R Adosraku British Journal of Pharmaceutical Research 11 (1), 1-21, 2016 | 72 | 2016 |
| Development of a tumor-responsive nanopolyplex targeting pancreatic cancer cells and stroma Y Li, Z Zhao, H Liu, JP Fetse, A Jain, CY Lin, K Cheng ACS applied materials & interfaces 11 (49), 45390-45403, 2019 | 45 | 2019 |
| Recent advances in the development of therapeutic peptides J Fetse, S Kandel, UF Mamani, K Cheng Trends in Pharmacological Sciences 44 (7), 425-441, 2023 | 39 | 2023 |
| Discovery of cyclic peptide inhibitors targeting PD-L1 for cancer immunotherapy J Fetse, Z Zhao, H Liu, UF Mamani, B Mustafa, P Adhikary, M Ibrahim, ... Journal of medicinal chemistry 65 (18), 12002-12013, 2022 | 30 | 2022 |
| Wound healing activity of total alkaloidal extract of the root bark of Alstonia boonei (Apocynacea) JP Fetse, JO Kyekyeku, E Dueve, KB Mensah British Journal of Pharmaceutical Research 4 (23), 2642-2652, 2014 | 30 | 2014 |
| Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity P Adhikary, S Kandel, UF Mamani, B Mustafa, S Hao, J Qiu, J Fetse, Y Liu, ... Advanced Therapeutics 4 (7), 2100087, 2021 | 25 | 2021 |
| Targeted delivery of an siRNA/PNA hybrid nanocomplex reverses carbon tetrachloride‐induced liver fibrosis A Jain, A Barve, Z Zhao, JP Fetse, H Liu, Y Li, K Cheng Advanced therapeutics 2 (8), 1900046, 2019 | 25 | 2019 |
| Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery P Patel, J Fetse, CY Lin, Y Guo, MR Hasan, M Nakhjiri, Z Zhao, A Jain, ... Acta biomaterialia 154, 374-384, 2022 | 19 | 2022 |
| Synthesis and characterization of novel xylopic acid derivatives W Kofie, JP Fetse, RK Adosraku American Chemical Science Journal 16 (2), 1-12, 2016 | 7 | 2016 |
| Antimicrobial activities of novel xylopic acid derivatives W Kofie, JP Fetse, RK Adosraku JAMB 14 (1), 1-6, 2019 | 4 | 2019 |
| Discovery of Anti‐CD47 Peptides as Innate Immune Checkpoint Inhibitors B Mustafa, J Fetse, S Kandel, C Yu Lin, P Adhikary, UF Mamani, Y Liu, ... Advanced Therapeutics, 2300114, 2023 | 1 | 2023 |
| Evidence for the anxiolytic-and antidepressant-like effects of three semi-synthetic derivatives of xylopic acid in mice CK Benneh, WKM Abotsi, PK Mante, RP Biney, JP Fetse, MK Abeka, ... Naunyn-Schmiedeberg's Archives of Pharmacology, 1-20, 2025 | | 2025 |
| Development of a peptide-based tumor-activated checkpoint inhibitor for cancer immunotherapy Z Zhao, J Fetse, UF Mamani, Y Guo, Y Li, P Patel, Y Liu, CY Lin, Y Li, ... Acta Biomaterialia, 2024 | | 2024 |
| Exploring Multivalency in the Development of Anti-PD-L1 Peptides for Cancer Immunotherapy UF Mamani, MN Ibrahim, Y Liu, J Fetse, CY Lin, S Kandel, M Nakhjiri, ... Pharmaceutical Research 41 (12), 2275-2288, 2024 | | 2024 |
| Personalized Medicine Approach to Proteomics and Metabolomics of Cytochrome P450 Enzymes: A Narrative Review J Fetse, EO Olawode, S Deb European Journal of Drug Metabolism and Pharmacokinetics 49 (6), 661-676, 2024 | | 2024 |
| Pharmacoproteomics and Drug Target Discovery PS Agogo-Mawuli, EY Afful, J Fetse, DP Siderovski Pharmacoproteomics: Recent Trends and Applications, 35–48, 2024 | | 2024 |
| Development of an aerosol-based immunotherapy for lung cancer Y Li, Z Zhao, J Fetse, R Hasan, UF Mamani, Y Guo, K Cheng Cancer Research 83 (7_Supplement), 5183-5183, 2023 | | 2023 |
| Polypeptides And Compositions Comprising The Same K Cheng, H Liu, J Fetse, UF Mamani US Patent App. 17/507,301, 2022 | | 2022 |
| Discovery and Delivery of Peptide-Based Immune Checkpoint Inhibitors Targeting PD-L1 for Cancer Immunotherapy JP Fetse University of Missouri-Kansas City, 2022 | | 2022 |